DSS News & Events

DSS announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1M, before deducting underwriting fees and other offering expenses payable by the Company. The offering consists of 900,000 shares of common stock. The public offering price per share of common stock is $1.00. In addition, the Company has granted the underwriter an overallotment option to purchase up to an additional 135,000 shares of common stock, representing 15% of the number of shares offered, which option is exercisable in whole or in part at any time up to 45 days after the date of this prospectus. Aggregate gross proceeds to the Company are expected to be approximately $900,000, or $1.035M if the over-allotment option is exercised in full. The transaction is expected to close on or about February 5, 2026, subject to the satisfaction of customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering.

Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.

DSS announced that its subsidiary, Impact BioMedical, has entered into a definitive merger agreement with Dr. Ashleys. Under the terms of the agreement, Dr. Ashleys will acquire Impact through a reverse merger that will result in a newly formed combined entity traded on the NYSE American under the name "Dr Ashleys Limited." The combination of Dr. Ashleys' extensive pharmaceutical manufacturing and commercialization capabilities with Impact BioMedical's innovation-driven platform positions the combined company to accelerate the development of groundbreaking therapies. Under the terms of the Merger Agreement, a series of conversion and equity alignment actions are contemplated to simplify ownership and strengthen DSS's strategic position in the newly formed public entity immediately prior to closing. This includes the conversion of Impact's Series A Preferred Stock, the exercise of DSS's debt-to-equity rights under its promissory note, and the cancellation of in-the-money Impact options and warrants for Impact shares. These shares, including those held by DSS, will be converted into PubCo ordinary shares, representing 4.80% of the combined company's total outstanding shares at closing. Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact, with Impact being the surviving entity. Simultaneously with or immediately following the merger, the PubCo shall acquire all of the issued and outstanding shares of Dr. Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr. Ashleys, with a new Board of Directors to be assembled by Dr. Ashleys. The Boards of Directors of both Dr. Ashleys and Impact have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact's shareholders, and satisfaction of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission and the approval of listing applications with the New York Stock Exchange.

Reports Q1 revenue $4.95M vs. $3.87M last year. "These results show clear, measurable progress in the financial realignment strategy we launched earlier this year," said Jason Grady, CEO of DSS, Inc. "In my January letter to shareholders, I outlined the urgent need to cut inefficiencies, strengthen our balance sheet, and lay the groundwork for sustained growth. This quarter proves that work is paying off. As we continue to streamline operations, we're now turning our attention toward execution in our core verticals and identifying smart, accretive opportunities that will drive long-term value. The foundation is in place and now we're building on it."